703 related articles for article (PubMed ID: 30053956)
1. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
[TBL] [Abstract][Full Text] [Related]
2. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
Hozawa S; Terada M; Haruta Y; Hozawa M
Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
[TBL] [Abstract][Full Text] [Related]
3. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
Bernstein D; Andersen L; Forth R; Jacques L; Yates L
J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
Adachi M; Goldfrad C; Jacques L; Nishimura Y
Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
[TBL] [Abstract][Full Text] [Related]
5. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
7. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
[TBL] [Abstract][Full Text] [Related]
9. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
Matera MG; Capuano A; Cazzola M
Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy.
Albertson TE; Bullick SW; Schivo M; Sutter ME
Drug Des Devel Ther; 2016; 10():4047-4060. PubMed ID: 28008228
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
12. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
Oliver AJ; Covar RA; Goldfrad CH; Klein RM; Pedersen SE; Sorkness CA; Tomkins SA; Villarán C; Grigg J
Respir Res; 2016 Apr; 17():37. PubMed ID: 27044326
[TBL] [Abstract][Full Text] [Related]
13. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
[TBL] [Abstract][Full Text] [Related]
15. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
[TBL] [Abstract][Full Text] [Related]
17. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
Bateman ED; O'Byrne PM; Busse WW; Lötvall J; Bleecker ER; Andersen L; Jacques L; Frith L; Lim J; Woodcock A
Thorax; 2014 Apr; 69(4):312-9. PubMed ID: 24253831
[TBL] [Abstract][Full Text] [Related]
18. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs.
Averell CM; Stanford RH; Laliberté F; Wu JW; Germain G; Duh MS
J Asthma; 2021 Jan; 58(1):102-111. PubMed ID: 31607180
[TBL] [Abstract][Full Text] [Related]
19. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
[TBL] [Abstract][Full Text] [Related]
20. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
Bakerly ND; Woodcock A; Collier S; Leather DA; New JP; Crawford J; Harvey C; Vestbo J; Boucot I
Respir Med; 2019 Feb; 147():58-65. PubMed ID: 30704700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
